|
PFE's Operating Income Growth by Quarter and Year
Pfizer Inc's Operating Income results by quarter and year
|
Select the Comparisons :
|
|
Select the Ratio:
|
Operating Income Growth Y/Y▼
|
Operating Income Growth Y/Y▼
|
| PFE Operating Income (in millions $) |
FY 2023 |
FY 2022 |
FY 2021 |
FY 2020 |
| IV Quarter |
January |
-
|
4,454.00
|
3,001.00
|
341.00
|
| III Quarter |
October |
-3,363.00
|
9,467.00
|
6,142.00
|
3,324.00
|
| II Quarter |
July |
1,954.00
|
12,220.00
|
5,611.00
|
3,091.00
|
| I Quarter |
April |
6,361.00
|
9,756.00
|
4,679.00
|
4,105.00
|
| FY |
|
4,952.00
|
35,897.00
|
19,433.00
|
10,861.00
|
| PFE Operating Income third quarter 2023 Y/Y Growth Comment |
Pfizer Inc in the third quarter 2023 recorded Operating Loss of $ -3,363.00 millions.
Looking into third quarter 2023 results within Major Pharmaceutical Preparations industry 8 other companies have achieved higher Operating Income growth. While Pfizer Inc' s Operating Income no change of % ranks overall at the positon no. 632 in the third quarter 2023.
Explain Operating Income growth
|
| PFE Operating Income ( Y/Y Growth %) |
2023
|
2022 |
2021 |
2020 |
| IV Quarter |
January |
- |
48.42 % |
780.06 % |
-77.79 % |
| III Quarter |
October |
- |
54.14 % |
84.78 % |
-69.9 % |
| II Quarter |
July |
-84.01 % |
117.79 % |
81.53 % |
-27.54 % |
| I Quarter |
April |
-34.8 % |
108.51 % |
13.98 % |
-7 % |
| FY |
|
- |
84.72 % |
78.92 % |
-48.91 % |
PFE Operating Income (Quarter on Quarter Growth %) |
2023
|
2022 |
2021 |
2020 |
| IV Quarter |
January |
- |
-52.95 % |
-51.14 % |
-89.74 % |
| III Quarter |
October |
- |
-22.53 % |
9.46 % |
7.54 % |
| II Quarter |
July |
-69.28 % |
25.26 % |
19.92 % |
-24.7 % |
| I Quarter |
April |
42.82 % |
225.09 % |
1272.14 % |
167.43 % |
| FY (Year on Year) |
|
- |
84.72 % |
78.92 % |
-48.91 % |
| Operating Income Y/Y Growth Statistics |
| High |
Average |
Low |
| 123 % |
8.86 % |
-72.69 % |
| (Jul 03 2022) |
|
|
|
|
| Operating Income Y/Y Growth Statistics |
| High |
Average |
Low |
| 123 % |
8.86 % |
-72.69 % |
| (Jul 03 2022) |
|
|
|
| Operating Income by Quarter for the Fiscal Years 2020, 2021, 2022, 2023 |
Pfizer Inc's Q/Q Operating Income Growth
| Operating Income Q/Q Growth Statistics |
| High |
Average |
Low |
| 0 % |
0 % |
0 % |
|
|
|
| PFE's III. Quarter Q/Q Operating Income Comment |
Current accomplishment of -3,363.00 millions by Pfizer Inc appear even more unfavourable considering the 1,954.00 millions in the previous quarter.
Within Major Pharmaceutical Preparations industry Pfizer Inc achieved highest sequential Operating Income growth. While Pfizer Inc's Operating Income growth quarter on quarter, overall rank is . |
|
|
|
| Operating Income Q/Q Growth Statistics |
| High |
Average |
Low |
| 0 % |
0 % |
0 % |
|
|
|
| PFE's III. Quarter Q/Q Operating Income Comment |
Current accomplishment of -3,363.00 millions by Pfizer Inc come out even less good considering the Operating Loss 1,954.00 millions in the second quarter.
Within Major Pharmaceutical Preparations industry Pfizer Inc achieved highest sequential Operating Income growth. While Pfizer Inc's Operating Income growth quarter on quarter, overall rank is . |
|
Pfizer Inc's 12 Months Operating Income Growth Year on Year
Operating Income TTM Growth |
12 Months Ending
(Oct 01 2023) |
12 Months Ending
(Jul 02 2023) |
12 Months Ending
(Apr 02 2023) |
12 Months Ending
(Dec 31 2022) |
12 Months Ending
(Oct 02 2022) |
| Cumulative Operating Income 12 Months Ending |
$ 9,406.00 |
$ 22,236.00 |
$ 32,502.00 |
$ 35,897.00 |
$ 34,444.00 |
| Y / Y Operating Income Growth (TTM) |
-72.69 % |
-28.55 % |
32.61 % |
84.72 % |
105.35 % |
| Year on Year Operating Income Growth Overall
Ranking |
# 146 |
# 334 |
# 226 |
# 394 |
# 0 |
| Seqeuential Operating Income Change (TTM) |
-57.7 % |
-31.59 % |
-9.46 % |
4.22 % |
10.68 % |
| Seq. Operating Income Growth (TTM) Overall
Ranking |
# 632 |
# 1028 |
# 1397 |
# 882 |
# 0 |
| Cumulative Operating Income growth
Comment |
Pfizer Inc's cumulative 12 months Operating Income continue to drop, but on the faster rate at -72.69% year on year, at Oct 01 2023 compare to the -28.55% decrease at Jul 02 2023. If the Pfizer Inc's fiscal year would end at Oct 01 2023, annual Operating Income would be $9,406 millions.
Among companies within the Healthcare sector 5 other companies have achieved higher trailing twelve month Operating Income growth. While Total ranking has impoved so far to 146, from total ranking in previous quarter at 334. |
| Operating Income TTM Q/Q Growth Statistics |
| High |
Average |
Low |
123 % |
8.86 % |
-72.69 % |
|
|
|
|
|
| Operating Income TTM Y/Y Growth Statistics |
| High |
Average |
Low |
123 % |
8.86 % |
-72.69 % |
|
|
|
| Operating Income TTM Q/Q Growth Company Ranking |
| Within: |
No. |
| Industry |
# 9 |
| Sector |
# 37 |
| S&P 500 |
# 632 |
|
| Cumulative Operating Income growth
Comment |
Pfizer Inc's cumulative 12 months Operating Income continue to drop, but on the faster rate at -72.69% year on year, at Oct 01 2023 compare to the -28.55% decrease at Jul 02 2023. If the Pfizer Inc's fiscal year would end at Oct 01 2023, annual Operating Income would be $9,406 millions.
Among companies within the Healthcare sector 5 other companies have achieved higher trailing twelve month Operating Income growth. While Total ranking has impoved so far to 146, from total ranking in previous quarter at 334. |
| Operating Income TTM Q/Q Growth Statistics |
| High |
Average |
Low |
123 % |
8.86 % |
-72.69 % |
|
|
|
| Operating Income TTM Y/Y Growth Statistics |
| High |
Average |
Low |
123 % |
8.86 % |
-72.69 % |
|
|
|
| Operating Income TTM Q/Q Growth Company Ranking |
| Within: |
No. |
| Industry |
# 9 |
| Sector |
# 37 |
| S&P 500 |
# 632 |
|
